Literature DB >> 30155624

Stromal Cells in the Tumor Microenvironment.

Alice E Denton1, Edward W Roberts2, Douglas T Fearon3.   

Abstract

The tumor microenvironment comprises a mass of heterogeneous cell types, including immune cells, endothelial cells, and fibroblasts, alongside cancer cells. It is increasingly becoming clear that the development of this support niche is critical to the continued uncontrolled growth of the cancer. The tumor microenvironment contributes to the maintenance of cancer stemness and also directly promotes angiogenesis, invasion, metastasis, and chronic inflammation. In this chapter, we describe on the role of fibroblasts, specifically termed cancer-associated fibroblasts (CAFs), in the promotion and maintenance of cancers. CAFs have a multitude of effects on the growth and maintenance of cancer, and here we focus on their roles in modulating immune cells and responses; CAFs both inhibit immune cell access to the tumor microenvironment and inhibit their functions within the tumor. Finally, we describe the potential modulation of CAF function as an adjunct to bolster the effectiveness of cancer immunotherapies.

Entities:  

Keywords:  Cancer-associated fibroblast; Immunotherapy; Stromal immunology; Tumor microenvironment

Mesh:

Year:  2018        PMID: 30155624     DOI: 10.1007/978-3-319-78127-3_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  73 in total

1.  Tumor stemness and immune infiltration synergistically predict response of radiotherapy or immunotherapy and relapse in lung adenocarcinoma.

Authors:  Hongjie Shi; Linzhi Han; Jinping Zhao; Kaijie Wang; Ming Xu; Jiajun Shi; Zhe Dong
Journal:  Cancer Med       Date:  2021-11-05       Impact factor: 4.452

2.  The clinical relevance of unfolded protein response signaling in breast cancer.

Authors:  Masanori Oshi; Arya Mariam Roy; Shipra Gandhi; Yoshihisa Tokumaru; Li Yan; Akimitsu Yamada; Itaru Endo; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

Review 3.  New Technologies Bloom Together for Bettering Cancer Drug Conjugates.

Authors:  Yiming Jin; Shahab Edalatian Zakeri; Raman Bahal; Andrew J Wiemer
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

4.  Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports.

Authors:  Jun-Hui Guo; Yuan-Yuan Wang; Jiang-Wei Zhang; Pei-Min Liu; Yan-Jun Hao; Hai-Rui Duan
Journal:  World J Clin Cases       Date:  2020-04-06       Impact factor: 1.337

Review 5.  Targeting tumor vascularization: promising strategies for vascular normalization.

Authors:  Ruiqi Zheng; Feifan Li; Fengcen Li; Aihua Gong
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-19       Impact factor: 4.553

Review 6.  The evolving landscape of N6-methyladenosine modification in the tumor microenvironment.

Authors:  Yunru Gu; Xi Wu; Jingxin Zhang; Yuan Fang; Yutian Pan; Yongqian Shu; Pei Ma
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

Review 7.  Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy.

Authors:  Wen-Jun Zhang
Journal:  Purinergic Signal       Date:  2021-01-09       Impact factor: 3.765

8.  SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells.

Authors:  Suhong Xia; Jingwen Wu; Wangdong Zhou; Mingyu Zhang; Kai Zhao; Jingmei Liu; Dean Tian; Jiazhi Liao
Journal:  Cell Death Dis       Date:  2021-06-02       Impact factor: 8.469

9.  A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.

Authors:  Jie Wu; Lan Li; Huibo Zhang; Yaqi Zhao; Haohan Zhang; Siyi Wu; Bin Xu
Journal:  Oncogene       Date:  2021-06-09       Impact factor: 9.867

10.  Effect of silencing C-erbB-2 on esophageal carcinoma cell biological behaviors by inhibiting IGF-1 pathway activation.

Authors:  Zhigao Niu; Wenping Zhang; Jialun Shi; Xiangdong Li; Hanlei Wu
Journal:  J Cardiothorac Surg       Date:  2021-07-07       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.